Clinical Trial Update: Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial in triple-negative breast cancer evaluating dose-dense EC followed by ABX plus a PD-1 inhibitor; the study is currently active but not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• ABX
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Epirubicin (epirubicin)
• PD-1 inhibitor

Snippet

Sponsor: Fudan University | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING